Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic efficacy of adoptive immunotherapy

3 Dec 2021

Abstract excerpt

Adoptive cancer immunotherapy can induce objective clinical efficacy in patients with advanced cancer; however, a sustained response is achieved in a minority of cases. The persistence of infused T cells is an essential determinant of a durable therapeutic response. Antitumor T cells undergo a genome-wide remodeling of the epigenetic architecture upon repeated antigen encounters, which inevitably induces...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34861037
DOI: 10.1182/blood.2021012714

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic efficacy of adoptive immunotherapyPMID 34861037Read ↗

BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustionSemantic proximity Read ↗

Genetic and Epigenetic Regulation of PD-1 ExpressionSemantic proximity Read ↗

Role of PRDM1 in Tumor Immunity and Drug Response: A Pan-Cancer AnalysisSemantic proximity Read ↗

PRDM1/BLIMP1: a tumor suppressor gene in B and T cell lymphomasSemantic proximity Read ↗

Gene editing technology to improve antitumor T-cell functions in adoptive immunotherapySemantic proximity Read ↗

The Crossroads of Cancer Epigenetics and Immune Checkpoint TherapySemantic proximity Read ↗

Functional delineation of tissue-resident CD8 <sup>+</sup> T cell heterogeneity during infection and cancerSemantic proximity Read ↗

EPDR1 promotes PD-L1 expression and tumor immune evasion by inhibiting TRIM21-dependent ubiquitylation of IkappaB kinase-βSemantic proximity Read ↗

PRMT1 acts as a suppressor of MHC-I and anti-tumor immunitySemantic proximity Read ↗

MLLT6 maintains PD‐L1 expression and mediates tumor immune resistanceSemantic proximity Read ↗

CRISPR screens establish regulatory maps of immunosuppressive surface molecules in cancerSemantic proximity Read ↗

Fas ligand-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.